Update on idiopathic anaphylaxis.
allergens
idiopathic anaphylaxis
mast cells
mastocytosis
Journal
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
ISSN: 1399-3038
Titre abrégé: Pediatr Allergy Immunol
Pays: England
ID NLM: 9106718
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
28
07
2021
received:
10
06
2021
accepted:
06
08
2021
entrez:
26
1
2022
pubmed:
27
1
2022
medline:
1
4
2022
Statut:
ppublish
Résumé
Idiopathic anaphylaxis (AI) refers to anaphylaxis without a recognizable cause after a comprehensive allergic workup. The diagnostic approach usually includes an accurate clinical history aimed at excluding both the most and the less frequent causes of anaphylaxis and all pathologies that may resemble anaphylaxis. AI is more common in adults than in children. The epidemiology of AI has been reduced in recent years, probably to increase knowledge and discover new clinical entities, such as the α-gal anaphylaxis. Anaphylaxis results from the massive activation of the mast cells (MCs). Thus, it is also necessary to exclude MC disorders, such as mastocytosis and mast cell activation syndrome, and α-tryptasemia, which may manifest with IA symptoms.
Substances chimiques
Tryptases
EC 3.4.21.59
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
52-53Informations de copyright
© 2022 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Bilò MB, Martini M, Tontini C, Mohamed OE, Krishna MT. Idiopathic anaphylaxis. Clin Exp Allergy. 2019;49:942-952.
Pattanaik D, Lieberman P, Lieberman J, Pongdee T, Keene AT. The changing face of anaphylaxis in adults and adolescents. Ann Allergy Asthma Immunol. 2018;121:594-597.
Gulen T, Akin C. Idiopathic anaphylaxis: a perplexing diagnostic challenge for allergist. Curr Allergy Asthma Immunol. 2021;21:11.
Fenny N, Grammer LC. Idiopathic anaphylaxis. Immunol Allergy Clin North Am. 2015;35:349-362.
Lange M, Hartmann K, Carter MC, et al. Molecular background, clinical features and management of pediatric mastocytosis: status. Int J Mol Sci. 2021;22:2586.
Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. 2008;54-63.
Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Practice. 2019;7:1125-1133.
Robey RC, Wilcock M, Bonin H, et al. Hereditary alpha-tryptasemia: UK prevalence and variability in disease expression. J Allergy Clin Immunol Pract. 2020;8:3549-3556.
Lyons JJ, Chovanec J, O'Connell MP, et al. Heritable risk for severe anaphylaxis associated with increased α-tryptase-encoding germline copy number at TPSAB1. J Allergy Clin Immunol. 2021;147:622-632.
Carter MC, Maric I, Brittain EH, et al. A randomized, double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis. J Allergy Clin Immunol. 2021;147:1004-1010.